Table 2.

Genetic alterations in IDH-mutant glioma patients at MGH

PtAge at DxSexInitial histologyInitial WHO gradeOS (mos)PFS (mos)IDH1 mutationConfirmed secondary (lineage) alterationTreatment before detection of tertiary alterationTertiary alteration (amino acid substitution or copy number ratioa)
160MOligoastrocytomaII78.3b21.9R132HcodelRT; TMZ (18 cycles)AKT1 (E17K), KRAS (G12R), PIK3CA (H1047L)
241FAstrocytomaII165.1b54.0R132HcodelTMZ (12 cycles); RTKRAS (G13D)
333FOligodendrogliomaII159.8b159.8bR132HcodelPCV (6 cycles); RTKRAS G12R)
454MGBM-OIV38.4b25.7R132HcodelNoneKRAS (G12A)
543MOligodendrogliomaII180.4b172.9R132HcodelNonePIK3CA (R88Q)
651FOligodendrogliomaII28.3b24.6R132HcodelTMZ (12 cycles)PIK3CA (E545G)
730MAnaplastic oligoastrocytomaIII62.4b55.7R132HNAConcurrent RT/TMZ + adjuvant TMZ (12 cycles)PIK3CA (E542K)
838MAnaplastic oligoastrocytomaIII99.2b74.4R132HcodelConcurrent RT/TMZ + adjuvant TMZ (12 cycles); TMZ (10 cycles)PIK3CA (E545K)
939FAnaplastic oligodendrogliomaIII166.0b162.7R132Hno codelPCV (6 cycles); RTPIK3CA (R88Q)
1045FGBMIV8.1b8.1bR132HcodelNonePIK3CA (H1047Q)
1151MGBMIV0.7b0.7bR132HNANonePIK3CA (H1047R)
1229MGBM-OIV12.2b12.2bR132Hno codelNonePIK3CA (R93Q)
1334MAnaplastic oligoastrocytomaIII31.328.0R132HTP53 V272MConcurrent RT/TMZ + adjuvant TMZ (12 cycles)MET amplification (5:1 in 10–15% cells)
1452FGBMIV113.2b93.2R132HNAConcurrent RT/TMZ + adjuvant ddTMZ (25 cycles)MET amplification (>25:1 in 1/50 cells)
1533MGBM with PNET componentIV5.03.9R132HTP53 R273HNoneN-MYC amplification (>25:1)
1635MAnaplastic astrocytomaIII24.4b24.4bR132HTP53 R273CNonePDGFRA amplification (>25:1 in 1/200 cells)
1747MAnaplastic astrocytomaIII58.5b57.5R132Hno codelConcurrent RT/TMZ + adjuvant TMZ (6 cycles)PDGFRA amplification (>25:1)
1845MGBMIV25.6b25.6bR132HTP53 R273CNonePDGFRA amplification (>25:1)
1932FAstrocytomaII79.619.1R132HTP53 R273CRTPDGFRA amplification (>25:1)
2061MGBM-OIV9.4b9.4bR132HTP53 R273CNonePTEN (R173C)

Abbreviations: Pt, patient; Dx, diagnosis; OS, overall survival; mos, months; GBM-O, glioblastoma with oligodendroglioma component; codel, 1p/19q codeleted; TMZ, temozolomide; ddTMZ, dose dense temozolomide; RT, radiation therapy; NA, not available.

  • aRatio of specific gene probe to centromere control.

  • bEvent has not yet occurred.